Female patients with breast cancer aged 40 to 60 years old with pathologically confirmed breast cancer patients who met the CLINICAL practice guidelines for NCCN breast cancer (2018.v1); KPS score no less than 60 points, WBC no less than 4.0 × 109 before treatment, normal liver and renal function, expected survival above three months; All were pathologically confirmed breast cancer patients who met the CLINICAL practice guidelines for NCCN breast cancer (2018.v1) after modified radical mastectomy and received chemotherapy with AC regimen (adriamycin + cyclophosphamide) or TAC regimen (docetaxel + adriamycin + cyclophosphamide) for the first time. All the selected patients have signed informed consent and are willing to accept the treatment of this program.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.